Evidence map›Paper›PMID 25861259›Full record

ArticleGastroenterology research and practice2015

Myoxinol (Hydrolyzed Hibiscus esculentus Extract) in the Cure of Chronic Anal Fissure: Early Clinical and Functional Outcomes.

Adolfo Renzi, Antonio Brillantino, Giandomenico Di Sarno, Francesco D'Aniello, Stefania Ziccardi, Fiorella Paladino, Francesca Iacobellis

Open access · goldAbstract read
In one paragraph

Article in Gastroenterology research and practice, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 10 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Adolfo RenziPelvic Care Center, "Villa delle Querce" Hospital, Via Battistello Caracciolo 48, 80136 Naples, Italy.
Antonio BrillantinoPelvic Care Center, "Villa delle Querce" Hospital, Via Battistello Caracciolo 48, 80136 Naples, Italy ; "A. Cardarelli" Hospital, Via Antonio Cardarelli 9, 80131 Naples, Italy.ORCID 0000-0002-0198-8511
Giandomenico Di SarnoPelvic Care Center, "Villa delle Querce" Hospital, Via Battistello Caracciolo 48, 80136 Naples, Italy.
Francesco D'AnielloPelvic Care Center, "Villa delle Querce" Hospital, Via Battistello Caracciolo 48, 80136 Naples, Italy.
Stefania ZiccardiSecond University of Naples, Piazza Miraglia 2, 80138 Naples, Italy.
Fiorella Paladino"A. Cardarelli" Hospital, Via Antonio Cardarelli 9, 80131 Naples, Italy.
Francesca IacobellisRadiology Department, Second University of Naples, Piazza Miraglia 2, 80138 Naples, Italy.ORCID 0000-0003-4604-7384
Ospedale Antonio Cardarelli · ITUniversity of Campania "Luigi Vanvitelli" · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective. This study was designed to evaluate the early results of the topical application of Hydrolyzed Hibiscus esculentus Extract 3% ointment (Myoxinol 3%), a novel local product with Botox-like activity, in the conservative treatment of chronic anal fissure (CAF). Methods. Among all patients with CAF observed during the study period, 31 subjects met the inclusion criteria and underwent medical therapy with Myoxinol 3% ointment every 12 hours for 6 weeks. Two patients were lost to follow-up. Clinical and manometric follow-up was carried out eight weeks after treatment. Results. At follow-up the success rate was 72.4% (21/29); median VAS score and mean anal resting pressure were significantly lower if compared with respective baseline data. The only one adverse effect of the topical application of Myoxinol 3% ointment was perianal itch, which was reported by 3,4% (1/29) of the patients available for the analysis. However, in this case this symptom did not cause interruption of the treatment. Conclusions. The topical application of Myoxinol 3% ointment in the cure of CAF shows encouraging early results. Further researches with a larger series and a longer follow-up are needed to confirm these data.

Identifiers

PMID25861259
PMCPMC4378599
OpenAlexW2015074007

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.